P/E ratio for Mochida Pharmaceutical (4534.T)
P/E ratio as of March 2025 (TTM): 9.29
According to Mochida Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 9.29365. At the end of 2024 the company had a P/E ratio of 25.2.
P/E ratio history for Mochida Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 25.2 | 36.63% |
| 2023 | 18.5 | 32.39% |
| 2022 | 14.0 | -29.19% |
| 2021 | 19.7 | -49.42% |
| 2020 | 39.0 | 40.8% |
| 2019 | 27.7 | 68.14% |
| 2018 | 16.5 | -16.07% |
| 2017 | 19.6 | -4.65% |
| 2016 | 20.6 | -1.3% |
| 2015 | 20.8 | 36.11% |
| 2014 | 15.3 | 18.35% |
| 2013 | 12.9 | 14.08% |
| 2012 | 11.3 | -44.02% |
| 2011 | 20.3 | 96.76% |
| 2010 | 10.3 | -20.3% |
| 2009 | 12.9 | -2.21% |
| 2008 | 13.2 | -43.04% |
| 2007 | 23.2 | -21.3% |
| 2006 | 29.5 | -27.49% |
| 2005 | 40.6 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.